Nuformix (LON:NFX) Shares Up 9.2% – Should You Buy?

Nuformix plc (LON:NFX) shares shot up 9.2% during trading on Wednesday . The company traded as high as GBX 0.38 and last traded at GBX 0.28. 139,235,969 shares were traded during mid-day trading, an increase of 275% from the average session volume of 37,120,164 shares. The stock had previously closed at GBX 0.26.

Nuformix Stock Down 28.3%

The stock has a market cap of £4.54 million, a P/E ratio of -5.47 and a beta of 1.41. The firm has a 50 day moving average price of GBX 0.26 and a 200 day moving average price of GBX 0.24.

Nuformix (LON:NFX) last announced its quarterly earnings data on Tuesday, January 27th. The company reported GBX (0.04) earnings per share (EPS) for the quarter.

About Nuformix

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.